Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (61-70 of 209) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinomaYu-Ning Wong, Samuel Litwin, David Vaughn, et al.
Future Oncology (London, England)|October 26, 2023
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinomaToni K Choueiri, Thomas Powles, Martin H Voss, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based ApproachClair J Beard, Shilpa Gupta, Robert J Motzer, et al.
Clinical Genitourinary Cancer|December 3, 2014
A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSiteMatthew Zibelman, Peter Barth, Elizabeth Handorf, et al.
The Lancet. Oncology|January 14, 2017
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b studyElizabeth R Plimack, Joaquim Bellmunt, Shilpa Gupta, et al.
Investigational New Drugs|June 21, 2015
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumorsMatthew Zibelman, Yu-Ning Wong, Karthik Devarajan, et al.
The Oncologist|March 29, 2014
A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcomaElizabeth R Plimack, Tingting Tan, Yu-Ning Wong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
Distress and Financial Distress in Adults With Cancer: An Age-Based AnalysisCaitlin R Meeker, Yu-Ning Wong, Brian L Egleston, et al.
Cancer Medicine|December 19, 2015
Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinomaDaniel M Geynisman, Elizabeth Handorf, Yu-Ning Wong, et al.
JAMA Oncology|June 1, 2016
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical TrialSaby George, Robert J Motzer, Hans J Hammers, et al.
Pageof 21

Showing results (61-70 of 209) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinomaYu-Ning Wong, Samuel Litwin, David Vaughn, et al.
Future Oncology (London, England)|October 26, 2023
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinomaToni K Choueiri, Thomas Powles, Martin H Voss, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based ApproachClair J Beard, Shilpa Gupta, Robert J Motzer, et al.
Clinical Genitourinary Cancer|December 3, 2014
A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSiteMatthew Zibelman, Peter Barth, Elizabeth Handorf, et al.
The Lancet. Oncology|January 14, 2017
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b studyElizabeth R Plimack, Joaquim Bellmunt, Shilpa Gupta, et al.
Investigational New Drugs|June 21, 2015
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumorsMatthew Zibelman, Yu-Ning Wong, Karthik Devarajan, et al.
The Oncologist|March 29, 2014
A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcomaElizabeth R Plimack, Tingting Tan, Yu-Ning Wong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
Distress and Financial Distress in Adults With Cancer: An Age-Based AnalysisCaitlin R Meeker, Yu-Ning Wong, Brian L Egleston, et al.
Cancer Medicine|December 19, 2015
Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinomaDaniel M Geynisman, Elizabeth Handorf, Yu-Ning Wong, et al.
JAMA Oncology|June 1, 2016
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical TrialSaby George, Robert J Motzer, Hans J Hammers, et al.
Pageof 21